NFKB1 and neoplasm: To identify what confers ibrutinib sensitivity in mantle cell lymphoma with respect to NF-κB signaling, Saba et al. [17] analyzed the gene expression profiles of 55 tumor samples from 43 previously untreated patients with MCL that were about to undergo therapy.